Sudden cardiac death
- Roy M. John MD, PhD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sudden cardiac death is often due to a ventricular arrhythmia. When a patient presents with a malignant arrhythmia unrelated to a transient reversible cause, there is a high probability of recurrent arrhythmia and sudden death. Clinical trials have shown a uniform survival benefit from implantable cardioverter-defibrillator (ICD) therapy in survivors of a malignant arrhythmia when compared with drug therapy. However, only 1% to 5% of patients survive an out-of-hospital cardiac arrest, emphasizing the need for primary prevention of sudden death. Clinical trial data available in this regard are largely limited to patients with coronary artery disease (CAD). Mortality can be reduced by the ICD in patients with CAD and depressed left ventricular ejection fraction (LVEF) less than 30%. If left ventricular function is only moderately depressed (LVEF between 30% and 40%), the presence of nonsustained ventricular tachycardia with inducible ventricular arrhythmia at electrophysiologic testing identifies patients who benefit from an ICD. The role of the ICD in primary prevention of sudden death in patients with nonischemic dilated cardiomyopathy is less clear at this time. Preliminary data indicate that the presence of heart failure symptoms in this population increases risk of sudden death that can be prevented by an ICD. Antiarrhythmic drugs have little role in prevention of sudden death; however, drugs that block the effects of β-adrenergic stimulation, angiotensin, and aldosterone reduce mortality partly through their salutary effects on sudden death. Finally, a number of inherited defects of genes coding for ion channels, contractile sarcomeric proteins, and cell-to-cell junction proteins can result in primary electrical abnormalities and sudden death. The ICD is effective for secondary prevention, but its role in primary prevention is controversial and should be based on individual risk factors.
- Sra J, Dhala A, Blanck Z, et al.: Sudden cardiac death. Curr Probl Cardiol 1999, 24:461–538. A well-referenced monograph on sudden cardiac death. CrossRef
- Moss AJ: Implantable cardioverter defibrillator therapy. The sickest patients benefit the most. Circulation 2000, 101:1638–1640.
- The Antiarrhythmics versus implantable defibrillators (AVID) investigators. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias [no authors listed]. N Engl J Med 1997, 337:1576–1583.
- Ezekowitz JA, Armstrong PW, McAlister FA: Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003, 138:I40. A review of recent trials of ICD in secondary and primary prevention.
- Sleight P: Current options in the management of coronary artery disease. Am J Cardiol 2003, 92:4N-8N. CrossRef
- Moss AJ, Zareba W, Hall WJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877–883. CrossRef
- Kadish A, Dyer A, Daubert JP, et al.: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151–2158. CrossRef
- Maron BJ, Estes NA III, Maron MS, et al.: Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003, 107:2872–2875. CrossRef
- Nishimura RA, Holmes DR: Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004, 350:1320–1327. An up-to-date review of hypertrophic cardiomyopathy and its management. CrossRef
- Varnava AM, Elliot PM, Baboonian C, et al.: Hypertrophic cardiomyopathy. Histopathological features of sudden cardiac death in cardiac troponin T disease. Circulation 2001, 104:1380–1384.
- Corrado D, Fontaine G, Marcus FI, et al.: Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Circulation 2000, 101:E101-E106.
- Priori SG, Schwartz PJ, Napolitano C, et al.: Risk stratification in the long-QT syndrome. N Engl J Med 2003, 348:1866–1874. An analysis of risk factors for sudden arrhythmic events in 647 patients with long QT syndrome from 193 genotyped families. CrossRef
- Zareba W, Moss AJ, Daubert JP, et al.: Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol 2003, 14:337–341. CrossRef
- Gaita F, Giustetto C, Bianchi F, et al.: Short QT syndrome: a familial cause of sudden death. Circulation 2003, 108:965–970. CrossRef
- Antzelevitch C, Brugada P, Brugada J, et al.: Brugada syndrome 1992–2002: a historical perspective. J Am Coll Cardiol 2003, 41:1665–1671. An authoritative review of the cellular mechanisms, clinical features, and management of the Brugada syndrome. CrossRef
- Pappone C, Santinelli V, Manguso F, et al.: A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolf-Parkinson-White syndrome. N Engl J Med 2003, 349:1803–1811. CrossRef
- Steeds RP, Oakley D: Predicting late sudden death from ventricular arrhythmia in adults following repair of tetralogy of Fallot. Q J Med 2004, 97:7–13.
- Sudden cardiac death
Current Treatment Options in Cardiovascular Medicine
Volume 6, Issue 5 , pp 347-355
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Cardiology, Lahey Clinic Medical Center, 41 Mall Road, 01805, Burlington, MA, USA